Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aminosalicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.92 |
| ▸ | POLB | P06746 | 2/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminosalicylic Acid SCHEMBL29379024 | 0.96 | KDM4E (1.00) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL31065282 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL1047421 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL688206 | 0.96 | KDM4E (1.00) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL1457932 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL1477512 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL11788856 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL31598403 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL30724149 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT | |
| Aminosalicylic Acid SCHEMBL11795055 | 0.96 | KDM4E (0.92) | KDM4ETDP1POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12290608-B2 | Layered collagen dressing with extended bacteria and biofilm reducing capabilities | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-06 | — | — | US | claimed |
| CN-118599275-B | Flame-retardant antibacterial PETG material, preparation method and application thereof in medical packaging | 东莞市万塑成塑料有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-118599275-A | Flame-retardant antibacterial PETG material, preparation method and application thereof in medical packaging | 东莞市万塑成塑料有限公司 | 2024-09-06 | — | — | CN | claimed |
| EP-3990037-B1 | LAYERED COLLAGEN DRESSING WITH EXTENDED BACTERIA AND BIOFILM REDUCING CAPABILITIES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-06-19 | — | — | EP | claimed |
| EP-3990036-B1 | CITRIC ACID COATED WOUND DRESSING COMPOSITIONS AND METHODS OF MANUFACTURE | KCI LICENSING INC (US) | 2023-08-23 | — | — | EP | claimed |
| US-20220354987-A1 | COLLAGEN POLYSACCHARIDE WOUND DRESSING | SYSTAGENIX WOUND MANAGEMENT, LIMITED (GB) | 2022-11-10 | — | — | US | claimed |
| US-20220347339-A1 | LAYERED COLLAGEN DRESSING WITH EXTENDED BACTERIA AND BIOFILM REDUCING CAPABILITIES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-11-03 | — | — | US | claimed |
| US-20220347340-A1 | CITRIC ACID COATED WOUND DRESSING COMPOSITIONS AND METHODS OF MANUFACTURE | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-11-03 | — | — | US | claimed |
| US-20220218530-A1 | Perforated Collagen Wound Interface For Use With Negative Pressure Wound Therapy | KCI LICENSING INC (US) | 2022-07-14 | — | — | US | claimed |
| US-10143771-B2 | Antioxidant and antimicrobial wound dressing materials | KCI USA, INC. (US) | 2018-12-04 | — | — | US | claimed |
| EP-2376132-A2 | ABSORBENT MATERIAL | Speciality Fibres and Materials Limited (GB) | 2011-10-19 | — | — | EP | claimed |
| US-20110238025-A1 | Cellulose Ethylsulfonate-Based Absorbent Material | SPECIALITY FIBRES AND MATERIALS LTD. (GB) | 2011-09-29 | — | — | US | claimed |
| WO-2010061225-A2 | ABSORBENT MATERIAL | SPECIALITY FIBRES AND MATERIALS LIMITED (GB) | 2010-06-03 | — | — | WO | claimed |
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AVANOS MEDICAL SALES, LLC | 2009-02-05 | — | — | US | claimed |
| EP-1809264-A4 | ANTIMICROBIAL AMORPHOUS COMPOSITIONS | ACRYMED INC (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070254044-A1 | Antimicrobial Amorphous Compositions | ACRYMED, INC. (US) | 2007-11-01 | — | — | US | claimed |
| EP-1809264-A2 | ANTIMICROBIAL AMORPHOUS COMPOSITIONS | ACRYMED, INC. (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1781098-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2007-05-09 | — | — | EP | claimed |
| WO-2006034249-A2 | ANTIMICROBIAL AMORPHOUS COMPOSITIONS | ACRYMED, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| WO-2006015317-A2 | ANTIMICROBIAL DEVICES AND COMPOSITIONS | ACRYMED, INC. (US) | 2006-02-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035342-A1 | Antimicrobial Devices and Compositions | AAAS, AOC1, COL14A1 | KDM4E 4147/4885TDP1 4268/4885POLB 1429/4885 |
| US-20070254044-A1 | Antimicrobial Amorphous Compositions | CUTA, DSTN, NACA | KDM4E 4557/4885TDP1 3296/4885POLB 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.